Gyre Therapeutics Inc
GYRE6.730USD
+0.080+1.20%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
589.79MMarktkapitalisierung
81.34KGV TTM
mehr Informationen über Gyre Therapeutics Inc Unternehmen
Gyre Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in the research, development, manufacturing, and commercialization of drugs for organ fibrosis. It is primarily focused on the development and commercialization of F351 (Hydronidone) for the treatment of Nonalcoholic Steatohepatitis Treatment (NASH)-associated fibrosis. The Company is also advancing a diverse pipeline in the China through its indirect controlling interest in Gyre Pharmaceuticals, including ETUARY therapeutic expansions, F573, F528, and F230. The Company operates through two segments: Gyre Pharmaceuticals, and Gyre after the Contributions. The Gyre Pharmaceuticals has one major commercial drug product, ETUARY, and several product candidates in pre-clinical and clinical development. Gyre is a biopharmaceutical company focused on the development and commercialization of F351 for the treatment of non-alcoholic steatohepatitis-associated liver fibrosis in the United States.
Unternehmensinformationen
BörsenkürzelGYRE
Name des UnternehmensGyre Therapeutics Inc
IPO-datumApr 12, 2006
CEODr. Han Ying, Ph.D.
Anzahl der mitarbeiter574
WertpapierartOrdinary Share
GeschäftsjahresendeApr 12
Addresse12770 High Bluff Drive, Suite 150
StadtSAN DIEGO
BörseNASDAQ Capital Market Consolidated
LandUnited States of America
Postleitzahl92130
Telefon16199493681
Websitehttps://www.gyretx.com/
BörsenkürzelGYRE
IPO-datumApr 12, 2006
CEODr. Han Ying, Ph.D.
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Songjiang Ma
Mr. Songjiang Ma
President, Director
President, Director
2.84M
-3.64%
Mr. Weiguo Ye
Mr. Weiguo Ye
Chief Operating Officer
Chief Operating Officer
700.00K
+7.69%
Mr. Rodney L. Nussbaum
Mr. Rodney L. Nussbaum
Independent Director
Independent Director
--
--
Dr. David M. Epstein, Ph.D.
Dr. David M. Epstein, Ph.D.
Independent Director
Independent Director
--
--
Dr. Han Ying, Ph.D.
Dr. Han Ying, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Ms. Ruoyu Chen
Ms. Ruoyu Chen
Chief Financial Officer
Chief Financial Officer
--
-100.00%
Mr. Thomas Eastling
Mr. Thomas Eastling
Director
Director
--
--
Mr. Ping Zhang
Mr. Ping Zhang
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Mr. Gordon G. Carmichael, Ph.D.
Mr. Gordon G. Carmichael, Ph.D.
Independent Director
Independent Director
--
--
Dr. Renate Parry, Ph.D.
Dr. Renate Parry, Ph.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Songjiang Ma
Mr. Songjiang Ma
President, Director
President, Director
2.84M
-3.64%
Mr. Weiguo Ye
Mr. Weiguo Ye
Chief Operating Officer
Chief Operating Officer
700.00K
+7.69%
Mr. Rodney L. Nussbaum
Mr. Rodney L. Nussbaum
Independent Director
Independent Director
--
--
Dr. David M. Epstein, Ph.D.
Dr. David M. Epstein, Ph.D.
Independent Director
Independent Director
--
--
Dr. Han Ying, Ph.D.
Dr. Han Ying, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Ms. Ruoyu Chen
Ms. Ruoyu Chen
Chief Financial Officer
Chief Financial Officer
--
-100.00%
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Sun, Jul 6
Aktualisiert: Sun, Jul 6
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
GNI Group Ltd
82.60%
Luo (Ying)
3.22%
Ma (Songjiang)
3.22%
The Vanguard Group, Inc.
1.24%
Ye (Weiguo)
0.79%
Other
8.92%
Aktionäre
Aktionäre
Anteil
GNI Group Ltd
82.60%
Luo (Ying)
3.22%
Ma (Songjiang)
3.22%
The Vanguard Group, Inc.
1.24%
Ye (Weiguo)
0.79%
Other
8.92%
Aktionärstypen
Aktionäre
Anteil
Corporation
82.60%
Individual Investor
7.26%
Investment Advisor
2.11%
Investment Advisor/Hedge Fund
0.69%
Research Firm
0.19%
Hedge Fund
0.02%
Other
7.14%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
123
81.82M
92.88%
+8.77M
2025Q1
126
82.96M
94.19%
+9.94M
2024Q4
117
71.62M
76.58%
-277.10K
2024Q3
117
71.44M
76.41%
-69.01K
2024Q2
108
71.18M
81.40%
+2.80M
2024Q1
95
70.73M
80.87%
+2.43M
2023Q4
101
67.57M
93.09%
+2.43M
2023Q3
124
846.01K
34.20%
-1.22M
2023Q2
137
853.88K
34.77%
-909.13K
2023Q1
173
927.40K
37.69%
-976.07K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
GNI Group Ltd
72.77M
82.6%
+8.77M
+13.70%
Mar 12, 2025
Luo (Ying)
2.84M
3.22%
--
--
Sep 06, 2024
Ma (Songjiang)
2.84M
3.22%
-107.21K
-3.64%
Mar 12, 2025
The Vanguard Group, Inc.
1.10M
1.24%
+774.02K
+240.03%
Mar 31, 2025
Ye (Weiguo)
700.00K
0.79%
+50.00K
+7.69%
Apr 01, 2025
BlackRock Institutional Trust Company, N.A.
506.93K
0.58%
+12.53K
+2.53%
Mar 31, 2025
Geode Capital Management, L.L.C.
312.32K
0.35%
+8.22K
+2.70%
Mar 31, 2025
State Street Global Advisors (US)
128.77K
0.15%
+2.13K
+1.68%
Mar 31, 2025
SBI Securities Co., Ltd.
123.63K
0.14%
+22.39K
+22.12%
Mar 31, 2025
Charles Schwab Investment Management, Inc.
111.42K
0.13%
-3.15K
-2.75%
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Aug 2
Aktualisiert: Sat, Aug 2
Name
Anteil
iShares Russell 2000 Growth ETF
0.01%
iShares Core S&P Total U.S. Stock Market ETF
0%
ProShares UltraPro Russell2000
0%
Schwab U.S. Small-Cap ETF
0%
iShares Morningstar Small-Cap Value ETF
0%
iShares Russell 2000 ETF
0%
Avantis US Small Cap Equity ETF
0%
ProShares Hedge Replication ETF
0%
FlexShares Morningstar US Market Factor Tilt Index Fund
0%
iShares Russell 2000 Value ETF
0%
Mehr Anzeigen
iShares Russell 2000 Growth ETF
Anteil0.01%
iShares Core S&P Total U.S. Stock Market ETF
Anteil0%
ProShares UltraPro Russell2000
Anteil0%
Schwab U.S. Small-Cap ETF
Anteil0%
iShares Morningstar Small-Cap Value ETF
Anteil0%
iShares Russell 2000 ETF
Anteil0%
Avantis US Small Cap Equity ETF
Anteil0%
ProShares Hedge Replication ETF
Anteil0%
FlexShares Morningstar US Market Factor Tilt Index Fund
Anteil0%
iShares Russell 2000 Value ETF
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Oct 30, 2023
Merger
15<1
Oct 30, 2023
Merger
15<1
Oct 30, 2023
Merger
15<1
Oct 30, 2023
Merger
15<1
Datum
Art
Verhältnis
Oct 30, 2023
Merger
15<1
Oct 30, 2023
Merger
15<1
Oct 30, 2023
Merger
15<1
Oct 30, 2023
Merger
15<1
